These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19440008)

  • 1. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
    Novara G; Galfano A; Secco S; Ficarra V; Artibani W
    Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    Bolton EM; Lynch T
    BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal therapy of prostate cancer.
    Debruyne F
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):4-9. PubMed ID: 12198632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
    Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
    J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptorelin in the management of prostate cancer.
    Ploussard G; Mongiat-Artus P
    Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
    Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
    BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test.
    Hutson PR; Oettel K; Douglas J; Ritter M; Messing E; Staab MJ; Alberti D; Horvath D; Wilding G
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):373-7. PubMed ID: 17922273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do we define "castration" in men on androgen deprivation therapy?
    Itty S; Getzenberg RH
    Asian J Androl; 2020; 22(5):441-446. PubMed ID: 31997782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
    Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
    BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligard: leuprolide acetate in a novel sustained-release delivery system.
    Sartor O
    Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
    Merseburger AS; Hupe MC
    Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.